Amicus (FOLD) AI Stock Analysis

• Market Cap: $2.43B
• Dividend Yield: N/A
• Average Volume (3M): 4.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 25.35%
• EPS Growth: 69.35%
• Country: US
• Employees: 499
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 308,239,380
• 10 Day Avg. Volume: 3,283,369
• 30 Day Avg. Volume: 4,122,147
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 3.46
• Enterprise Value/Gross Profit: 3.83
• Enterprise Value/Ebitda: 59.84
• 1Y Price Target: $16.17
• Price Target Upside: 105.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 55 Neutral
• Price Target: $8.00 ▲(1.91% Upside)

Amicus Therapeutics' stock score is primarily influenced by its financial performance challenges, including high leverage and negative profitability. However, strong technical indicators provide a positive short-term outlook. The valuation remains a concern due to the negative P/E ratio and lack of dividend yield.

Positive Factors

Financial Performance

Amicus reported strong revenue growth and continued momentum in its core Pompe and Fabry disease franchises, positioning the company for GAAP profitability.

Market Expansion

Several additional ex-US launches are progressing, including in the Netherlands, which has the highest prevalence of Pompe disease in Europe.

Product Launches

Pombiliti+Opfolda launch is starting to gain traction with strong new patient starts across various global launches.

Negative Factors

Competition

Taking meaningful market share away from Sanofi's ERTs will remain a challenge.

Financial Challenges

FOLD reported a 2Q25 GAAP net loss of $24.4M, with an EPS of ($0.08), highlighting ongoing financial challenges.

Revenue Guidance

FY25 total revenue guidance was lowered from +17-24% at CER to +15-22% at CER due to an unexpectedly higher UK VPAG rebate rate.

Amicus Business Overview & Revenue Model

Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Amicus Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by selling its approved therapies directly to healthcare providers and through partnerships with larger pharmaceutical companies that may involve co-development or licensing agreements. Key revenue streams include sales of its lead products, such as Galafold (migalastat) for Fabry disease, which has been approved in various markets. Additionally, Amicus may receive milestone payments and royalties from collaborations with partners, contributing to its overall financial performance. The company's ability to secure reimbursement agreements with insurance providers and government healthcare programs also plays a critical role in its revenue generation.

Amicus Financial Statement Overview

Summary

Amicus shows strong revenue growth and gross profit margins, but persistent net losses and high debt levels indicate financial instability. Cash flow metrics are improving, but profitability and financial flexibility remain challenges.

Income Statement

The company shows a positive revenue growth trend with a TTM (Trailing-Twelve-Months) revenue of $543.1 million, up from $528.3 million in the previous annual period. Gross profit margin remains strong at approximately 91%. However, the net profit margin is negative due to consistent net losses, indicating profitability challenges. EBIT and EBITDA margins have improved but remain low, suggesting limited operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is relatively high, indicating significant leverage, which could pose a financial risk. The equity ratio stands at 24.5%, showing a moderate proportion of equity financing. The return on equity is negative due to net losses, highlighting the company's struggle to generate returns for shareholders.

Cash Flow

The free cash flow has turned positive in the TTM period, showing improvement from the previous annual period. The operating cash flow to net income ratio is positive, indicating some level of cash generation from operations. However, the free cash flow to net income ratio remains low, pointing to challenges in converting earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	571.16M	528.29M	399.36M	329.23M	305.51M	260.89M
Gross Profit	516.13M	475.35M	362.03M	290.63M	271.05M	229.84M
EBITDA	33.06M	29.39M	-92.08M	-199.58M	-202.87M	-242.98M
Net Income	-38.10M	-56.11M	-151.58M	-236.57M	-250.46M	-276.85M
Balance Sheet
Total Assets	815.30M	785.03M	777.88M	724.17M	905.14M	886.52M
Cash, Cash Equivalents and Short-Term Investments	231.00M	249.95M	286.20M	293.60M	482.50M	483.27M
Total Debt	443.31M	443.64M	445.06M	452.12M	440.13M	441.73M
Total Liabilities	611.00M	590.99M	617.71M	601.12M	597.77M	600.14M
Stockholders Equity	204.30M	194.04M	160.17M	123.05M	307.37M	286.38M
Cash Flow
Free Cash Flow	-48.91M	-37.44M	-76.53M	-170.34M	-206.38M	-236.52M
Operating Cash Flow	-45.66M	-33.89M	-69.09M	-166.57M	-202.49M	-233.29M
Investing Cash Flow	-24.76M	-560.00K	98.06M	92.32M	78.76M	-13.58M
Financing Cash Flow	7.19M	5.12M	61.68M	-7.46M	212.07M	262.86M

Amicus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOLD, the sentiment is Positive. The current price of 7.85 is above the 20-day moving average (MA) of 7.34, above the 50-day MA of 6.61, and below the 200-day MA of 7.90, indicating a neutral trend. The MACD of 0.34 indicates Negative momentum. The RSI at 71.07 is Negative, neither overbought nor oversold. The STOCH value of 78.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOLD.

Amicus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APLS	58 Neutral	$3.56B	―	-108.49%	―	20.02%	33.45%
FOLD	55 Neutral	$2.43B	―	-22.62%	―	25.35%	69.35%
RARE	54 Neutral	$2.89B	―	-182.60%	―	26.77%	24.18%
CRNX	52 Neutral	$3.14B	―	-36.94%	―	―	-9.10%
Sector *	51 Neutral	$7.90B	-0.33	-41.70%	2.23%	23.45%	-1.99%
SRRK	50 Neutral	$3.18B	―	-172.08%	―	―	-29.50%
IMVT	45 Neutral	$2.63B	―	-77.58%	―	―	-48.38%

Amicus Corporate Events

Amicus Stockholders Approve Directors and Equity Plan

At the 2025 Annual Meeting of Stockholders held on June 5, 2025, Amicus‘s stockholders elected four Class III directors for a three-year term and approved the 2025 Equity Incentive Plan. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation on an advisory basis.